156 related articles for article (PubMed ID: 21679375)
21. Discovery of new β-D-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.
Abu Khalaf R; Abdula AM; Mubarak MS; Taha MO
J Mol Model; 2011 Mar; 17(3):443-64. PubMed ID: 20490878
[TBL] [Abstract][Full Text] [Related]
22. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
23. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
Shahin R; Taha MO
Bioorg Med Chem; 2012 Jan; 20(1):377-400. PubMed ID: 22112539
[TBL] [Abstract][Full Text] [Related]
24. Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.
Suaifan GA; Shehadehh M; Al-Ijel H; Taha MO
J Mol Graph Model; 2012 Jul; 37():1-26. PubMed ID: 22609742
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
Al-Sha'er MA; Taha MO
Eur J Med Chem; 2010 Sep; 45(9):4316-30. PubMed ID: 20638755
[TBL] [Abstract][Full Text] [Related]
26. Discovery of potent adenosine A2a antagonists as potential anti-Parkinson disease agents. Non-linear QSAR analyses integrated with pharmacophore modeling.
Khanfar MA; Al-Qtaishat S; Habash M; Taha MO
Chem Biol Interact; 2016 Jul; 254():93-101. PubMed ID: 27216633
[TBL] [Abstract][Full Text] [Related]
27. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
28. Selective peptidic and peptidomimetic inhibitors of Candida albicans myristoylCoA: protein N-myristoyltransferase: a new approach to antifungal therapy.
Sikorski JA; Devadas B; Zupec ME; Freeman SK; Brown DL; Lu HF; Nagarajan S; Mehta PP; Wade AC; Kishore NS; Bryant ML; Getman DP; McWherter CA; Gordon JI
Biopolymers; 1997; 43(1):43-71. PubMed ID: 9174411
[TBL] [Abstract][Full Text] [Related]
29. Current state of three-dimensional characterisation of antifungal targets and its use for molecular modelling in drug design.
Ruge E; Korting HC; Borelli C
Int J Antimicrob Agents; 2005 Dec; 26(6):427-41. PubMed ID: 16289513
[TBL] [Abstract][Full Text] [Related]
30. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
Habash M; Taha MO
Bioorg Med Chem; 2011 Aug; 19(16):4746-71. PubMed ID: 21788139
[TBL] [Abstract][Full Text] [Related]
31. Modeling robust QSAR. 1. Coding molecules in 3D-QSAR--from a point to surface sectors and molecular volumes.
Gieleciak R; Magdziarz T; Bak A; Polanski J
J Chem Inf Model; 2005; 45(5):1447-55. PubMed ID: 16180922
[TBL] [Abstract][Full Text] [Related]
32. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
[TBL] [Abstract][Full Text] [Related]
33. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.
Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD
J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500
[TBL] [Abstract][Full Text] [Related]
34. [N-myristoyltransferase: a novel antifungal target].
Zhu J; Sheng CQ; Zhang WN
Yao Xue Xue Bao; 2005 Sep; 40(9):775-81. PubMed ID: 16342675
[No Abstract] [Full Text] [Related]
35. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
36. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
Aboalhaija NH; Zihlif MA; Taha MO
Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606
[TBL] [Abstract][Full Text] [Related]
37. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM).
Peng T; Pei J; Zhou J
J Chem Inf Comput Sci; 2003; 43(1):298-303. PubMed ID: 12546565
[TBL] [Abstract][Full Text] [Related]
38. Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
Al-Najjar BO; Wahab HA; Tengku Muhammad TS; Shu-Chien AC; Ahmad Noruddin NA; Taha MO
Eur J Med Chem; 2011 Jun; 46(6):2513-29. PubMed ID: 21482446
[TBL] [Abstract][Full Text] [Related]
39. Structure-based quantitative structure--activity relationship modeling of estrogen receptor β-ligands.
Dong X; Hilliard SG; Zheng W
Future Med Chem; 2011 Jun; 3(8):933-45. PubMed ID: 21707397
[TBL] [Abstract][Full Text] [Related]
40. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling.
Taha MO; Qandil AM; Zaki DD; AlDamen MA
Eur J Med Chem; 2005 Jul; 40(7):701-27. PubMed ID: 15935905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
